Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials [0.03%]
早期乳腺癌试验中不宜得出 surrogate end points （替身结局指标）的结论
Saroj Niraula
Saroj Niraula
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer [0.03%]
早期乳腺癌试验中评估无侵袭性疾病生存期作为总生存期替代终点的方法学考量
Xiao-Jing Li,Guo Yu,Guo-Fu Li
Xiao-Jing Li
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer" [0.03%]
关于“早期乳腺癌试验中过度的替代终点结论”及“作为早期乳腺癌试验总生存期替代终点的无侵袭性疾病生存期的方法学考虑”的评论
Fabio Conforti,Vincenzo Bagnardi,Isabella Sala
Fabio Conforti
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma [0.03%]
与嫌色肾细胞癌抗肿瘤免疫抑制有关的肿瘤内在和微环境因素
Chris Labaki,Eddy Saad,Katrine N Madsen et al.
Chris Labaki et al.
Purpose: While immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC (ChRCC) and renal oncocy...
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) [0.03%]
BRUIN CLL-321：布鲁顿酪氨酸激酶共价抑制剂经治的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的III期PIRTOBI试验的更正公告
Jeff P Sharman,Talha Munir,Sebastian Grosicki et al.
Jeff P Sharman et al.
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 [0.03%]
德鲁替利姆单抗联合派姆单抗治疗PD-1抑制剂耐药的晚期黑色素瘤患者：Ⅱ期临床研究SPOTLIGHT-203
Iván Márquez-Rodas,Caroline Dutriaux,Philippe Saiag et al.
Iván Márquez-Rodas et al.
Purpose: Patients with anti-PD-1-resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally...
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) [0.03%]
肿瘤免疫治疗替萨伊珠单抗联合易普利姆玛对比单用易普利姆玛治疗转移性黑色素瘤III期开放性临床试验的更正：ILLUMINATE-301研究
Adi Diab,Paolo A Ascierto,Michele Maio et al.
Adi Diab et al.
Enduring Economic Effects of a Cancer Diagnosis in Adolescence and Young Adulthood [0.03%]
青少年及年轻成人癌症患者的持久经济影响
Danielle Novetsky Friedman,Bridgette Thom
Danielle Novetsky Friedman
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma [0.03%]
高危多发性骨髓瘤的定义国际骨髓学会/国际骨髓工作组共识建议的勘误说明
Hervé Avet-Loiseau,Faith E Davies,Mehmet K Samur et al.
Hervé Avet-Loiseau et al.
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study [0.03%]
他克莫司难治或依赖的慢性移植物抗宿主病患者中鲁索利替尼的三期研究（REACH3）三年最终分析
Robert Zeiser,Domenico Russo,Ron Ram et al.
Robert Zeiser et al.
In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients rece...